Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis receives EU approval for biosimilar Zessly

Novartis’ Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.

Read More »

Gilead, Verily to Tackle Three Inflammatory Diseases

Gilead Sciences and Google/Alphabet’ Verily Life Sciences teamed up to focus on three inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.

Read More »

Celltrion Shares Fall After FDA Issues Warning Letter

Shares of South Korea-based Celltrion were down more than 5 percent after the company announced it received a warning letter from the U.S. Food and Drug Administration after the regulatory agency inspected a company drug manufacturing facility.

Read More »

Pfizer’s Xeljanz Gets FDA Nod As Joint Disease Treatment

The U.S. FDA approved two doses of Pfizer Inc.’s medicine Xeljanz for treating active psoriatic arthritis.

Read More »

Merck profit beat clouded by NotPetya attack, shares dip

Merck & Co. reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda, but total revenue fell in third-quarter 2017 from disruptions due to the NotPetya cyber attack and loss of market share for many of the company’s older drugs.

Read More »

Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.’s Keytruda

Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.

Read More »

Biosimilar version of Humira approved in Europe

A biosimilar version of AbbVie Inc.’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc. and Samsung Biologics, was approved by EU regulators.

Read More »

GlaxoSmithKline’s new boss streamlines R&D

GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.

Read More »

Novartis gets European OK for biosimilar of Amgen’s Enbrel

Novartis’ generics unit Sandoz said the European Commission approved Erelzi – the company’s biosimilar to Amgen’s Enbrel – to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.

Read More »

EU backs second biosimilar copy of Humira

European regulators recommended approval of a second copy of AbbVie’s rheumatoid arthritis drug Humira, the world’s top-selling medicine.

Read More »

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to Humira

Boehringer Ingelheim announced results from the pivotal Phase III VOLTAIRE-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and Humira have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis.

Read More »

AbbVie’s RA drug succeeds in late-stage trial

AbbVie’s rheumatoid arthritis drug was superior to a placebo in a late-stage study involving patients that have not responded adequately to standard treatments.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation